Nurix Therapeutics, Inc. NRIX Capitalized research and experimental expenses
Capitalized research and experimental expenses at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept nrix:DeferredTaxAssetsCapitalizedResearchAndExperimentalExpenses.
The official record: Nurix Therapeutics, Inc.’s 10-K, filed January 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s capitalized research and experimental expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s capitalized research and experimental expenses?
- Nurix Therapeutics, Inc. (NRIX) reported capitalized research and experimental expenses of $132.84M in Q3 2025.
- What does capitalized research and experimental expenses mean?
- The amount of research and experimental expenditures that have been capitalized for tax purposes rather than expensed immediately. This reflects the tax treatment of R&D investments and impacts the company's deferred tax asset position.